Literature DB >> 18309034

Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century.

Hermann Brenner1, Adam Gondos, Dianne Pulte.   

Abstract

Although chronic lymphocytic leukemia (CLL) has remained incurable with standard treatments, newer therapeutic approaches, such as chemoimmunotherapy or stem cell transplantation, bear the potential for prolonged survival. We estimated trends in age-specific 5- and 10-year absolute and relative survival of CLL patients in the United States between 1980-1984 and 2000-2004 from the 1973 to 2004 database of the Surveillance, Epidemiology, and End Results Program. Period analysis was used to disclose recent developments with minimum delay. Overall, 5- and 10-year absolute survival from diagnosis increased from 54.2% to 60.2% (+6 percentage points; P < .0001) and from 27.8% to 34.8% (+7 percentage points; P < .0001), respectively. Despite a strong age gradient in prognosis, increases in 5-year absolute and relative survival over time were rather homogeneous across age groups. In contrast, increases in 10-year absolute and relative survival close to or well above 10% units were observed for all patients younger than 80 years of age at diagnosis compared with no increase at all for older patients. Long-term survival expectations of patients with CLL have substantially improved over the past 2 decades except for patients 80 years of age or older at the time of diagnosis. Future studies are needed to confirm and expand our findings.

Entities:  

Mesh:

Year:  2008        PMID: 18309034     DOI: 10.1182/blood-2007-12-129379

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  40 in total

Review 1.  Targeted therapy for chronic lymphocytic leukemia.

Authors:  Alfonso Quintás-Cardama; Susan O'Brien
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

2.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

3.  Chronic lymphocytic leukaemia: a-twenty-years experience and problems in Ile-Ife, South-Western Nigeria.

Authors:  L Salawu; R A Bolarinwa; M A Durosinmi
Journal:  Afr Health Sci       Date:  2010-06       Impact factor: 0.927

4.  Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia.

Authors:  Keith Tolley; Catherine Goad; Yunni Yi; Penny Maroudas; Amin Haiderali; Gwilym Thompson
Journal:  Eur J Health Econ       Date:  2012-09-01

Review 5.  Model-based cost-effectiveness analyses for the treatment of chronic lymphocytic leukaemia: a review of methods to model disease outcomes and estimate utility.

Authors:  Kevin Marsh; Peng Xu; Panagiotis Orfanos; James Gordon; Ingolf Griebsch
Journal:  Pharmacoeconomics       Date:  2014-10       Impact factor: 4.981

6.  Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia.

Authors:  Tait D Shanafelt; Kari G Rabe; Neil E Kay; Clive S Zent; Diane F Jelinek; Megan S Reinalda; Susan M Schwager; Debbie A Bowen; Susan L Slager; Curtis A Hanson; Timothy G Call
Journal:  Cancer       Date:  2010-10-15       Impact factor: 6.860

7.  Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985-2017).

Authors:  Neda Alrawashdh; Joann Sweasy; Brian Erstad; Ali McBride; Daniel O Persky; Ivo Abraham
Journal:  Ann Hematol       Date:  2021-07-19       Impact factor: 3.673

8.  Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts.

Authors:  Alexey V Danilov; Ryan S Soderquist; Darcy J P Bates; Alan Eastman
Journal:  Expert Rev Anticancer Ther       Date:  2013-09       Impact factor: 4.512

Review 9.  Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Authors:  Alexey V Danilov
Journal:  Clin Ther       Date:  2013-09       Impact factor: 3.393

10.  Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era.

Authors:  Anthony Mato; Jordan Jahnke; Pengxiang Li; Maneesha Mehra; Vrushabh P Ladage; Michelle Mahler; Scott Huntington; Jalpa A Doshi
Journal:  Haematologica       Date:  2018-04-26       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.